{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:14:56Z","timestamp":1792800896162,"version":"4.5.0"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"vor","delay-in-days":13,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.clinthera.2026.09.008","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:47:50Z","timestamp":1790110070000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Evaluation of Adverse Reactions of Roxadustat and Daprodustat: A Pharmacovigilance Study"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-7564-9540","authenticated-orcid":false,"given":"Fangwei","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaozhuang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liting","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunming","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4147-6617","authenticated-orcid":false,"given":"Shan","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2026.09.008_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/S2214-109X(23)00570-3","article-title":"An update on the global disparities in kidney disease burden and care across world countries and regions","volume":"12","author":"Bello","year":"2024","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.clinthera.2026.09.008_bib0002","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s12325-020-01524-6","article-title":"Burden of anemia in chronic kidney disease: beyond erythropoietin","volume":"38","author":"Hanna","year":"2021","journal-title":"Adv Ther"},{"key":"10.1016\/j.clinthera.2026.09.008_bib0003","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1056\/NEJMoa2025956","article-title":"Safety and efficacy of vadadustat for anemia in patients undergoing dialysis","volume":"384","author":"Eckardt","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2026.09.008_bib0004","article-title":"Anemia in chronic kidney disease: from pathophysiology and current treatments, to future agents","volume":"8","author":"Portol\u00e9s","year":"2021","journal-title":"Front Med (Lausanne)."},{"key":"10.1016\/j.clinthera.2026.09.008_bib0005","doi-asserted-by":"crossref","first-page":"3559","DOI":"10.1007\/s11255-024-04146-x","article-title":"Renal anemia: from relative insufficiency of EPO to imbalance of erythropoiesis and eryptosis","volume":"56","author":"Yuan","year":"2024","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.clinthera.2026.09.008_bib0006","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0325616","article-title":"Rapid increase in erythropoiesis-stimulating agent resistance is a risk factor for poor renal prognosis in patients with chronic kidney disease pre-dialysis: a BRIGHTEN study sub-analysis","volume":"20","author":"Kawamoto","year":"2025","journal-title":"PLoS One"},{"key":"10.1016\/j.clinthera.2026.09.008_bib0007","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s12325-024-03015-4","article-title":"Hyporesponsiveness to erythropoiesis-stimulating agents in dialysis-dependent patients with anaemia of chronic kidney disease: a retrospective observational study","volume":"42","author":"Atzinger","year":"2025","journal-title":"Adv Ther"},{"key":"10.1016\/j.clinthera.2026.09.008_bib0008","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1056\/NEJMoa1005109","article-title":"Erythropoietic response and outcomes in kidney disease and type 2 diabetes","volume":"363","author":"Solomon","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2026.09.008_bib0009","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/ki.2008.295","article-title":"Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes","volume":"74","author":"Szczech","year":"2008","journal-title":"Kidney Int"},{"key":"10.1016\/j.clinthera.2026.09.008_bib0010","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1021\/acs.bioconjchem.5c00037","article-title":"Fc multisite conjugation and prolonged delivery of the folate-targeted drug conjugate EC140","volume":"36","author":"Zheng","year":"2025","journal-title":"Bioconjugate Chem"},{"key":"10.1016\/j.clinthera.2026.09.008_bib0011","first-page":"2990","article-title":"IMN4NPD: an integrated molecular networking workflow for natural product dereplication","volume":"96","author":"Sheng","year":"2024","journal-title":"Anal Chem"},{"key":"10.1016\/j.clinthera.2026.09.008_bib0012","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12859-024-06032-w","article-title":"CDPMF-DDA: contrastive deep probabilistic matrix factorization for drug-disease association prediction","volume":"26","author":"Tang","year":"2025","journal-title":"BMC Bioinformatics"},{"key":"10.1016\/j.clinthera.2026.09.008_bib0013","doi-asserted-by":"crossref","first-page":"bbac006","DOI":"10.1093\/bib\/bbac006","article-title":"Biomedical data, computational methods and tools for evaluating disease-disease associations","volume":"23","author":"Xiang","year":"2022","journal-title":"Brief Bioinform"},{"key":"10.1016\/j.clinthera.2026.09.008_bib0014","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1093\/ndt\/gfae075","article-title":"Hypoxia-inducible factor prolyl hydroxylase inhibitors for anaemia in chronic kidney disease: a clinical practice document by the European Renal Best Practice board of the European Renal Association","volume":"39","author":"Stoumpos","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.clinthera.2026.09.008_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105020","article-title":"Efficacy and safety of HIF prolyl-hydroxylase inhibitor vs epoetin and darbepoetin for anemia in chronic kidney disease patients not undergoing dialysis: a network meta-analysis","volume":"159","author":"Zheng","year":"2020","journal-title":"Pharmacol Res."},{"key":"10.1016\/j.clinthera.2026.09.008_bib0016","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.3390\/biomedicines12122926","article-title":"Efficacy of hypoxia-inducible factor prolyl-hydroxylase inhibitors in renal anemia: enhancing erythropoiesis and long-term outcomes in patients with chronic kidney disease","volume":"12","author":"Yoshida","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.clinthera.2026.09.008_bib0017","article-title":"Impact of roxadustat on anemia management in infected patients undergoing long-term dialysis: a retrospective cohort analysis","volume":"16","author":"Wang","year":"2025","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.clinthera.2026.09.008_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbrc.2023.149387","article-title":"Investigating the therapeutic effects and mechanisms of roxadustat on peritoneal fibrosis based on the TGF-\u03b2\/Smad pathway","volume":"693","author":"Wang","year":"2024","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.clinthera.2026.09.008_bib0019","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.3390\/ph17081053","article-title":"An evaluation of sex-specific pharmacokinetics and bioavailability of kokusaginine: an in vitro and in vivo investigation","volume":"17","author":"Shang","year":"2024","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.clinthera.2026.09.008_bib0020","first-page":"1","article-title":"Retrospective analysis of clinical features of liver injury induced by levofloxacin","author":"Wu","year":"2025","journal-title":"Expert Opin Drug Saf."},{"key":"10.1016\/j.clinthera.2026.09.008_bib0021","doi-asserted-by":"crossref","DOI":"10.1080\/0886022X.2025.2491655","article-title":"HIF-PHIs associated with embolic and thrombotic events: a real-world pharmacovigilance study based on the Japan Adverse Drug Event Report database","volume":"47","author":"Wu","year":"2025","journal-title":"Ren Fail"},{"key":"10.1016\/j.clinthera.2026.09.008_bib0022","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1080\/14740338.2025.2465873","article-title":"Cardiovascular toxicities of hypoxia-inducible factor prolyl hydroxylase inhibitors: a disproportionality analysis based on JADER database","volume":"24","author":"Wu","year":"2025","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.clinthera.2026.09.008_bib0023","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/jat.4892","article-title":"Exploring the diagnostic potential of core targets of 6PPD and its metabolite 6PPD-Q in cardiovascular diseases: an integrated analysis based on network toxicology, molecular docking, and in vitro validation","volume":"46","author":"Guo","year":"2026","journal-title":"J Appl Toxicol"},{"key":"10.1016\/j.clinthera.2026.09.008_bib0024","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2025.2586335","article-title":"Pharmacovigilance analysis of FcRn antagonists in the treatment of myasthenia gravis: a disproportionality analysis based on the FAERS database","volume":"21","author":"Liu","year":"2025","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.clinthera.2026.09.008_bib0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10637-026-01596-1","article-title":"Clinical features, treatment and outcomes of pembrolizumab induced autoimmune hemolytic anemia","volume":"44","author":"Liu","year":"2026","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.clinthera.2026.09.008_bib0026","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1186\/s12879-026-12952-0","article-title":"Association between low-dose trimethoprim-sulfamethoxazole blood concentration and clinical outcomes in non-HIV patients with Pneumocystis jirovecii pneumonia: a retrospective cohort study","volume":"26","author":"Deng","year":"2026","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.clinthera.2026.09.008_bib0027","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.21873\/invivo.14277","article-title":"Drug-induced aseptic meningitis: pharmacovigilance analysis of Japanese adverse event reporting database","volume":"40","author":"Masago","year":"2026","journal-title":"In Vivo"},{"key":"10.1016\/j.clinthera.2026.09.008_bib0028","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.clinthera.2025.09.009","article-title":"Assessment of adverse events of teplizumab: a real-world pharmacovigilance study based on the FDA adverse event reporting system","volume":"47","author":"Wang","year":"2025","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2026.09.008_bib0029","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.clinthera.2025.12.013","article-title":"Safety assessment of budesonide\/formoterol: real-world pharmacovigilance analysis using the FAERS, JADER, and CVAR databases","volume":"48","author":"Chen","year":"2026","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2026.09.008_bib0030","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s40360-025-00902-6","article-title":"Safety profile of faricimab: a multi-source pharmacovigilance analysis using FAERS and JADER","volume":"26","author":"Liu","year":"2025","journal-title":"BMC Pharmacol Toxicol"},{"key":"10.1016\/j.clinthera.2026.09.008_bib0031","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1002\/jcph.2300","article-title":"Disproportionality analysis on hypothyroidism with roxadustat using the Japanese adverse drug event database","volume":"63","author":"Kouki","year":"2023","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2026.09.008_bib0032","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgad483","article-title":"Effect of roxadustat on thyroid function in patients with renal anemia","volume":"109","author":"Haraguchi","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2026.09.008_bib0033","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.isci.2019.10.002","article-title":"Revealing a mutant-induced receptor allosteric mechanism for the thyroid hormone resistance","volume":"20","author":"Yao","year":"2019","journal-title":"iScience"},{"key":"10.1016\/j.clinthera.2026.09.008_bib0034","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.beem.2013.10.003","article-title":"Pitfalls in the measurement and interpretation of thyroid function tests","volume":"27","author":"Koulouri","year":"2013","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2026.09.008_bib0035","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s12882-021-02304-2","article-title":"Suppression of thyrotropin secretion during roxadustat treatment for renal anemia in a patient undergoing hemodialysis","volume":"22","author":"Ichii","year":"2021","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.clinthera.2026.09.008_bib0036","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1093\/ckj\/sfab007","article-title":"Roxadustat and thyroid-stimulating hormone suppression","volume":"14","author":"Tokuyama","year":"2021","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.clinthera.2026.09.008_bib0037","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1056\/NEJMoa2113379","article-title":"Daprodustat for the treatment of anemia in patients undergoing dialysis","volume":"385","author":"Singh","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2026.09.008_bib0038","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1681\/ASN.2020081150","article-title":"Roxadustat for treating anemia in patients with CKD not on dialysis: results from a randomized phase 3 study","volume":"32","author":"Fishbane","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.clinthera.2026.09.008_bib0039","article-title":"Cerebral infarction after switching from roxadustat to daprodustat in a patient with renal anemia","volume":"16","author":"Takebayashi","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.clinthera.2026.09.008_bib0040","article-title":"Ischemic stroke during daprodustat therapy for renal anemia: a report of three cases","volume":"16","author":"Uchio","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.clinthera.2026.09.008_bib0041","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1186\/s12882-025-04561-x","article-title":"Network meta-analysis of HIF-prolyl hydroxylase inhibitors for anemia in dialysis-dependent and non-dialysis CKD: effects on hemoglobin, iron markers, and adverse clinical outcomes","volume":"26","author":"Nasiri","year":"2025","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.clinthera.2026.09.008_bib0042","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-47942-8","article-title":"Long-term HIF-1\u03b1 stabilization reduces respiration, promotes mitophagy, and results in retinal cell death","volume":"13","author":"Nsiah","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.clinthera.2026.09.008_bib0043","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1172\/JCI126655","article-title":"Roles of HIFs and VEGF in angiogenesis in the retina and brain","volume":"129","author":"Rattner","year":"2019","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clinthera.2026.09.008_bib0044","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1001\/jamainternmed.2022.0605","article-title":"Efficacy and safety of daprodustat for treatment of anemia of chronic kidney disease in incident dialysis patients: a randomized clinical trial","volume":"182","author":"Singh","year":"2022","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.clinthera.2026.09.008_bib0045","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.ekir.2022.01.1045","article-title":"Two phase 3 studies on ophthalmologic effects of roxadustat versus darbepoetin","volume":"7","author":"Sepah","year":"2022","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.clinthera.2026.09.008_bib0046","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/nep.13835","article-title":"Recommendations by the Asian Pacific Society of Nephrology (APSN) on the appropriate use of HIF-PH inhibitors","volume":"26","author":"Yap","year":"2021","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.clinthera.2026.09.008_bib0047","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1177\/1091581817737232","article-title":"Evaluation of the carcinogenic potential of roxadustat (FG-4592), a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase in CD-1 mice and Sprague Dawley rats","volume":"36","author":"Beck","year":"2017","journal-title":"Int J Toxicol"},{"key":"10.1016\/j.clinthera.2026.09.008_bib0048","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1177\/0192623319880445","article-title":"Carcinogenicity assessment of daprodustat (GSK1278863), a hypoxia-inducible factor (HIF)-prolyl hydroxylase inhibitor","volume":"48","author":"Adams","year":"2020","journal-title":"Toxicol Pathol"},{"key":"10.1016\/j.clinthera.2026.09.008_bib0049","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa2113380","article-title":"Daprodustat for the treatment of anemia in patients not undergoing dialysis","volume":"385","author":"Singh","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2026.09.008_bib0050","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.2215\/CJN.16191020","article-title":"Efficacy and cardiovascular safety of roxadustat for treatment of anemia in patients with non-dialysis-dependent CKD: pooled results of three randomized clinical trials","volume":"16","author":"Provenzano","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.clinthera.2026.09.008_bib0051","doi-asserted-by":"crossref","first-page":"sfad298","DOI":"10.1093\/ckj\/sfad298","article-title":"Comparison of outcomes on hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) in anaemia associated with chronic kidney disease: network meta-analyses in dialysis and non-dialysis dependent populations","volume":"17","author":"Sackeyfio","year":"2023","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.clinthera.2026.09.008_bib0052","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1111\/jcpt.13385","article-title":"Long-term efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitors in anaemia of chronic kidney disease: a meta-analysis including 13,146 patients","volume":"46","author":"Chen","year":"2021","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.clinthera.2026.09.008_bib0053","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1007\/s12325-023-02728-2","article-title":"Risk factors for thromboembolic events in patients with dialysis-dependent CKD: pooled analysis of four global roxadustat phase 3 trials","volume":"41","author":"Hamano","year":"2024","journal-title":"Adv Ther"},{"key":"10.1016\/j.clinthera.2026.09.008_bib0054","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1093\/ndt\/gfx011","article-title":"Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China","volume":"32","author":"Chen","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.clinthera.2026.09.008_bib0055","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMoa1901713","article-title":"Roxadustat treatment for anemia in patients undergoing long-term dialysis","volume":"381","author":"Chen","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2026.09.008_bib0056","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1053\/j.ajkd.2015.12.020","article-title":"Roxadustat (FG-4592) versus epoetin alfa for anemia in patients receiving maintenance hemodialysis: a phase 2, randomized, 6- to 19-week, open-label, active-comparator, dose-ranging, safety and exploratory efficacy study","volume":"67","author":"Provenzano","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.clinthera.2026.09.008_bib0057","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/1744-9987.12888","article-title":"Intermittent oral dosing of roxadustat in peritoneal dialysis chronic kidney disease patients with anemia: a randomized, phase 3, multicenter, open-label study","volume":"24","author":"Akizawa","year":"2020","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.clinthera.2026.09.008_bib0058","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1681\/ASN.2014111139","article-title":"Four-week studies of oral hypoxia-inducible factor-prolyl hydroxylase inhibitor GSK1278863 for treatment of anemia","volume":"27","author":"Holdstock","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.clinthera.2026.09.008_bib0059","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1053\/j.ajkd.2015.11.021","article-title":"A novel hypoxia-inducible factor-prolyl hydroxylase inhibitor (GSK1278863) for anemia in CKD: a 28-day, phase 2A randomized trial","volume":"67","author":"Brigandi","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.clinthera.2026.09.008_bib0060","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/ckj\/sfy014","article-title":"Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants on hemodialysis","volume":"12","author":"Meadowcroft","year":"2019","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.clinthera.2026.09.008_bib0061","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1186\/s12882-019-1547-z","article-title":"A randomized, 29-day, dose-ranging, efficacy and safety study of daprodustat, administered three times weekly in patients with anemia on hemodialysis","volume":"20","author":"Bailey","year":"2019","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.clinthera.2026.09.008_bib0062","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1159\/000454818","article-title":"Effects of daprodustat, a novel hypoxia-inducible factor prolyl hydroxylase inhibitor on anemia management in Japanese hemodialysis subjects","volume":"45","author":"Akizawa","year":"2017","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.clinthera.2026.09.008_bib0063","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1186\/s12882-025-04557-7","article-title":"Comparative effectiveness of darbepoetin vs other agents in chronic kidney disease-related anemia: a systematic review and network meta-analysis","volume":"26","author":"Hassan","year":"2025","journal-title":"BMC Nephrol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291826003474?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291826003474?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:48:56Z","timestamp":1791316136000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291826003474"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":63,"alternative-id":["S0149291826003474"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2026.09.008","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of Adverse Reactions of Roxadustat and Daprodustat: A Pharmacovigilance Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2026.09.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}